Țară: Canada
Limbă: engleză
Sursă: Health Canada
TENOFOVIR DISOPROXIL FUMARATE; EMTRICITABINE
ANGITA PHARMA INC.
J05AR03
TENOFOVIR DISOPROXIL AND EMTRICITABINE
300MG; 200MG
TABLET
TENOFOVIR DISOPROXIL FUMARATE 300MG; EMTRICITABINE 200MG
ORAL
15G/50G
Prescription
NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS
Active ingredient group (AIG) number: 0251568001; AHFS:
APPROVED
2020-02-19
PRODUCT MONOGRAPH Pr AG-Emtricitabine / Tenofovir Disoproxil Fumarate Emtricitabine and Tenofovir Tablets 200 mg / 300 mg (Emtricitabine / Tenofovir disoproxil fumarate) House Standard Antiretroviral Agent Angita Pharma Inc. 1310 rue Nobel Boucherville, Quebec J4B 5H3, Canada Submission Control No.: 265244 Date of Preparation: November 28, 2022 AG-Emtricitabine / Tenofovir Disoproxil Fumarate (emtricitabine/tenofovir disoproxil fumarate) tablets Product Monograph Page 2 TABLE OF CONTENTS PART I. HEALTH PROFESSIONAL INFORMATION ............................................................................................. 3 SUMMARY PRODUCT INFORMATION ........................................................................................................... 3 INDICATIONS AND CLINICAL USE ................................................................................................................. 3 CONTRAINDICATIONS ....................................................................................................................................... 5 WARNINGS AND PRECAUTIONS ..................................................................................................................... 5 ADVERSE REACTIONS...................................................................................................................................... 14 DRUG INTERACTIONS ...................................................................................................................................... 22 DOSAGE AND ADMINISTRATION ................................................................................................................. 34 OVERDOSAGE ..................................................................................................................................................... 36 ACTION AND CLINICAL PHARMACOLOGY................................................................................................ 37 STORAGE AND STABILITY................................................................ Citiți documentul complet